Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

An Interview with Expert Clinician Dr. Fred Wigley

Jason Liebowitz, MD, FACR  |  Issue: January 2024  |  January 10, 2024

It is most important to finish an encounter with the question, “How are you handling things?” It takes time to openly discuss the emotional impact of the illness, but it is most important. It is common to discover distress that is not mentioned. These days, I see the eyes begin to tear behind the COVID face masks.

The patient-doctor relationship is unique, based on trust and a special type of loving friendship. All my clinical activity is held together by a passion for my work, a clear understanding of my limitations, a willingness to seek help from my colleagues, a desire to understand the biology behind the clinical events and a constant attempt to do whatever is needed to comfort and improve my patient’s quality of life. I still have a view that what I decided today may not be ideal and refreshing my view of the problem and my treatment should be reviewed at each encounter.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

I am pretty sure that listening and being available to provide comfort to my patients are very powerful medications.

TR: Who were some of your clinician role models and what qualities did you admire in these individuals?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Wigley: When I was in high school, my family physician was Dr. Louis Michaelos, a tall, handsome, Greek man with thick, dark eyebrows and a gentle manner who looked like the doctor I hoped to become. Later, while in medical school, I spent a month-long rotation working in his office and began to learn some of the skills I use today. He would always start the encounter by taking the vital signs himself, telling me, “It is most important to gently touch your patient so you connect.” He was aware of his limitations as a primary care physician and made referrals so the patient got the expert help that they needed.

In medical school, I worked with Robert Waldman, MD, who was an immunologist and did his clinical training at Johns Hopkins. He helped me appreciate the importance of understanding basic biology and applying it to the care of patients; he also launched my clinical research career.

During my training at Johns Hopkins there were many who influenced me, including my colleague Ernest Arnett, MD. There were many talented members of the faculty, including Philip Tumulty, MD; Victor McKusick, MD; and C. Lockard Conley, MD. Dr. Conley was an incredibly gifted scientist and clinician who discovered the lupus anticoagulant.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:OpinionProfiles Tagged with:Dr. Fred WigleyRole Models in Rheumatology

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Targeted Therapy for Scleroderma Fibrosis

    October 11, 2016

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences